Too soon: Cherry blossom peak bloom ?. Not soon enough: Eli Lilly’s insulin price reduction ?.

Welcome To The Week In Review.

  1. The Inflation Reduction Act Keeps Bringing Relief

 2. Both Chambers Are Looking Into PBMs

3. Thank You, Taxpayers

4. More Patent Abuse By Big Pharma

5. Significant Savings From The Inflation Reduction Act

The drug price reforms in the Inflation Reduction Act provide savings to patients, employers, employees, and the government. A new Congressional Budget Office (CBO) report estimates that the new drug price law will save people on Medicare $25 billion and will reduce the federal deficit by $237 billion from 2022 to 2031. “This really does demonstrate the cost savings for both seniors and the Medicare program,” says Megan O’Reilly, AARP vice president for health and family issues. CBO emphasizes the impact of the law for people on Medicare, who will have better ability to afford and access their medications, leading to a decreased need for other medical care such as hospital visits. CBO also expects prices on negotiated drugs to drop by about 50 percent. Senators ManchinMurray, and Markey spread the word this week about how the Inflation Reduction Act will provide relief from high drug prices for patients in their states. “This law is going to be life changing—and lifesaving—for so many seniors and people with disabilities who rely on Medicare,” Senator Murray shared at a roundtable. The reforms are wildly popular — 79 percent of voters across party lines support the $35 monthly insulin copay caps which will be especially impactful to people of color, who are disproportionately affected by diabetes. The savings from the historic drug price law are long-awaited. — (Congressional Budget OfficeAARPOffice of Senator Joe ManchinOffice of Senator Patty MurrayBoston HeraldData For ProgressWisPolitics

Have a great weekend, everyone!